Stago

Executive Summary

Stago, founded in 1945 and headquartered in Asnières-sur-Seine, France, is a privately held diagnostics company specializing in hemostasis and thrombosis analysis. With a legacy spanning over seven decades, Stago provides advanced analyzer and reagent systems trusted by clinical and research laboratories worldwide. The company's deep expertise in coagulation diagnostics positions it as a key player in a niche but critical segment of in vitro diagnostics, serving the growing demand for precise and rapid hemostasis testing in areas such as anticoagulant monitoring, thrombophilia, and bleeding disorders. Looking ahead, Stago is well-positioned to capture growth from an aging global population and rising prevalence of thrombotic diseases. The company's innovation pipeline includes next-generation analyzers with enhanced automation and connectivity, as well as expanded reagent menus for emerging biomarkers. Stago's strong brand and established distribution network in Europe and select international markets provide a solid foundation. Key near-term catalysts include the launch of a new high-throughput hemostasis system, potential FDA clearance for a novel thrombosis assay, and strategic distribution partnerships to expand into Asia-Pacific. These initiatives are expected to strengthen Stago's competitive positioning and drive revenue growth in a market valued at over $5 billion.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation hemostasis analyzer70% success
• Q4 2026FDA clearance for a novel thrombosis diagnostic test60% success
• H2 2026Strategic partnership for distribution in Asia-Pacific65% success